These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 15776134)
1. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Sayani FA; Prosser C; Bailey RJ; Jacobs P; Fedorak RN Can J Gastroenterol; 2005 Mar; 19(3):147-51. PubMed ID: 15776134 [TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine. Zhu Q; Cao Q Chin Med J (Engl); 2012 Oct; 125(20):3665-70. PubMed ID: 23075721 [TBL] [Abstract][Full Text] [Related]
3. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304 [TBL] [Abstract][Full Text] [Related]
4. The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases. Hlavaty T; Batovsky M; Balakova D; Pav I; Celec P; Gregus M; Zakuciova M; Hlista M; Horakova M; Desatova B; Koller T; Toth J; Kadasi L; Huorka M; Bratisl Lek Listy; 2013; 114(4):199-205. PubMed ID: 23514552 [TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564 [TBL] [Abstract][Full Text] [Related]
6. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442 [TBL] [Abstract][Full Text] [Related]
7. [Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites]. Alvarez Beltran M; Infante Pina D; Tormo Carnicé R; Segarra Cantón O; Redecillas Ferreiro S An Pediatr (Barc); 2009 Feb; 70(2):126-31. PubMed ID: 19217567 [TBL] [Abstract][Full Text] [Related]
8. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects. Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571 [TBL] [Abstract][Full Text] [Related]
9. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA; Roberts RL; Kennedy MA Aliment Pharmacol Ther; 2003 Aug; 18(4):395-400. PubMed ID: 12940924 [TBL] [Abstract][Full Text] [Related]
10. Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease. Kim MJ; Lee SY; Choe YH Yonsei Med J; 2014 Sep; 55(5):1289-96. PubMed ID: 25048487 [TBL] [Abstract][Full Text] [Related]
11. Plasma thiopurine S-methyltransferase levels and azathioprine-related adverse events in patients with Behçet's disease. Emmungil H; Durusoy R; Kalfa M; Yargucu Zihni F; Özmen M; Keser G; Gücenmez S; Yilmaz Z; Aksu K Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S40-5. PubMed ID: 25936353 [TBL] [Abstract][Full Text] [Related]
12. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961 [TBL] [Abstract][Full Text] [Related]
13. [Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine]. Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM Med Clin (Barc); 2003 Jun; 121(1):1-5. PubMed ID: 12812701 [TBL] [Abstract][Full Text] [Related]
14. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981 [TBL] [Abstract][Full Text] [Related]
15. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Lindqvist M; Hindorf U; Almer S; Söderkvist P; Ström M; Hjortswang H; Peterson C Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1033-7. PubMed ID: 17065060 [TBL] [Abstract][Full Text] [Related]
16. Genetic Predictors of Azathioprine Toxicity and Clinical Response in Patients with Inflammatory Bowel Disease. Al-Judaibi B; Schwarz UI; Huda N; Dresser GK; Gregor JC; Ponich T; Chande N; Mosli M; Kim RB J Popul Ther Clin Pharmacol; 2016; 23(1):e26-36. PubMed ID: 26950049 [TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Ansari A; Arenas M; Greenfield SM; Morris D; Lindsay J; Gilshenan K; Smith M; Lewis C; Marinaki A; Duley J; Sanderson J Aliment Pharmacol Ther; 2008 Oct; 28(8):973-83. PubMed ID: 18616518 [TBL] [Abstract][Full Text] [Related]
18. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Ansari A; Hassan C; Duley J; Marinaki A; Shobowale-Bakre EM; Seed P; Meenan J; Yim A; Sanderson J Aliment Pharmacol Ther; 2002 Oct; 16(10):1743-50. PubMed ID: 12269967 [TBL] [Abstract][Full Text] [Related]
19. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817 [TBL] [Abstract][Full Text] [Related]